Active Share (vs S&P 500): 99.9%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-12.1%
· vs SPY
-14.3%
· Prev Value $2.08B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-2.2%
· vs SPY
-4.3%
· Latest Value $2.15B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, Affinity Asset Advisors, LLC disclosed 112 equity positions with a combined reported value of $2.15B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 46.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were IWM ($277.89M), ROIV ($117.02M), SYRE ($113.88M). By sector, the heaviest allocations are Health Care 80.5%, Financials 1.4%. Versus the prior quarter, allocation shifted toward Other (+7.1pp) and away from Health Care (-7.1pp).
Versus the prior quarter, Affinity Asset Advisors, LLC opened 24 new positions, trimmed 29 and fully exited 20, a turnover rate of 55.3% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q3 2026 were IWM ($277.89M), XBI ($94.61M), ARVN ($15.86M).
Of the 20 positions fully exited versus the prior quarter, the largest were APGE ($131.00M), NUVL ($33.96M), FBRX ($24.34M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest Affinity Asset Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Affinity Asset Advisors, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 108 US equity positions with a combined value of $2.08B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Regulatory AUM (Form ADV): $2.45B as of 2026-07-27
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 2 private funds, of which 1 hedge funds
Website: affinityadv.com
Portfolio Structure
108 positions · $2.08B reported value (Q2 2026)
Top 10 holdings = 41.7% of reported value
Largest position: ROIV (ROIVANT SCIENCES LTD) at 6.4%
Average position size: $19.25M
Sector Tilt
Health Care 87.6%
Financials 1.3%
Materials 0.3%
(classified holdings cover 89% of value)
Quarterly Activity
Q2 2026: 19 new, 34 added, 31 reduced, 12 exited
24 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund expanded its portfolio (24 new positions, 112 total) with a strong tilt toward healthcare (80% of top-10 holdings), suggesting a bullish view on biotech/therapeutics. New ETF positions (IWM, XBI) indicate broader market exposure alongside sector-specific bets.
2. Key moves:
- Added: TRAX (+1.46% wt), XENE (+1.66% wt), AVTX (+0.74% wt), ORKA (+0.37% wt), ERAS (+0.81% wt).
- Reduced: ROIV (-0.93% wt), INSM (-0.33% wt).
- New: IWM (12.94% wt), XBI (4.41% wt).
3. Portfolio structure: Active, healthcare-heavy (90% of top-10), with moderate risk (mix of high-growth biotechs and diversified ETFs).
4. Per-holding one-liner:
- IWM: iShares Russell 2000 ETF (U.S. small-cap).
- ROIV: Roviant Sciences (biopharma, unverified).
- SYRE: Spyre Therapeutics (oncology, unverified).
- XBI: SPDR S&P Biotech ETF (biotech sector).
- ERAS: Erasca (cancer therapeutics, unverified).
- TRAX: First Tracks Bio (immunotherapy, unverified).
- XENE: Xenon Pharmaceuticals (pain therapeutics, unverified).
- INSM: Insmed (infectious disease, unverified).
- ORKA: Oruka Therapeutics (unverified).
- AVTX: Avalo Therapeutics (respiratory disease, unverified).
5. Style summary: Aggressive healthcare-focused fund adding biotech/ETF exposure while trimming select positions.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-16 13:42
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 70%R 70%F1 70%(modelled on 2026-Q2; 7/10 hit)
Low-confidence forecast
This fund replaces about 37% of its Top-10 each quarter and
backtests at F1 62% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-13.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.
Portfolio return+1.05%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+14.76%vs benchmark
Barra annualised vol27.6%Model estimate
Realised vol27.2%Annualised in window
Weighted beta1.18Raw exposure
Factor / specific risk71% / 29%Share of variance
Top-10 concentration94.2%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
+1.05%
Disclosed long book
QQQ synthetic benchmark
-13.72%
Liquidity-weighted constituents
Model universe, equal weight
+0.30%
Opportunity-cost reference
Excess return
+14.76%
Portfolio − benchmark
Arithmetic return sum
+1.50%
Difference vs compounded is the cross term
Weighted raw beta
1.18
Weighted holding betas
Realised volatility (annualised)
27.25%
Daily returns in window
Barra model volatility (annualised)
27.58%
Factor + specific
Factor share of variance
71.4%
Barra factors
Specific share of variance
28.6%
Stock residuals
Reported value
$702.3M
13F long US equity
2. Return attribution
The +1.50% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
-1.64%
-109.0%
Momentum & Growth
3
-3.41%
-227.3%
Volatility & Tail Risk
7
-0.27%
-17.9%
Industry
12
+8.89%
592.6%
Specific
1
-2.07%
-138.3%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Kurtosis
Style
+0.72
+6.97%
+5.05%
336.9%
Health Care
Industry
+0.60
+8.12%
+4.91%
327.3%
Other
Industry
+0.40
+10.06%
+3.98%
265.3%
Beta
Style
+0.33
+4.85%
+1.58%
105.4%
Non-linear Size
Style
+1.43
+0.91%
+1.31%
87.4%
Leverage (Downside Vol)
Style
-0.57
-1.82%
+1.04%
69.2%
Short-term Reversal
Style
+0.19
+0.79%
+0.15%
9.8%
Turnover
Style
-0.03
-4.77%
+0.13%
8.9%
Liquidity
Style
+0.34
+0.22%
+0.07%
4.9%
Growth
Style
-0.04
+1.57%
-0.06%
-4.0%
Residual Volatility
Style
-0.10
+2.66%
-0.27%
-18.3%
Size
Style
+0.31
-1.83%
-0.56%
-37.6%
Amihud Illiquidity
Style
+1.49
-0.40%
-0.60%
-40.1%
Max Drawdown
Style
+0.68
-1.96%
-1.32%
-88.2%
Mid Cap
Style
+1.17
-1.69%
-1.99%
-132.5%
Specific
Specific
—
—
-2.07%
-138.3%
Historical Volatility
Style
+0.21
-12.86%
-2.70%
-179.9%
Momentum
Style
+1.05
-3.34%
-3.50%
-233.2%
Skewness
Style
+0.86
-4.21%
-3.64%
-243.0%
3. Risk attribution
Annualised volatility is 27.58%; factor risk explains 71.4% of variance and specific risk 28.6%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
28.6%
+7.89%
7.9%
Other
Industry
+0.40
24.9%
+6.88%
6.9%
Health Care
Industry
+0.60
20.1%
+5.54%
5.5%
Momentum
Style
+1.05
9.4%
+2.59%
2.6%
Beta
Style
+0.33
7.3%
+2.00%
2.0%
Mid Cap
Style
+1.17
5.5%
+1.53%
1.5%
Leverage (Downside Vol)
Style
-0.57
2.0%
+0.55%
0.6%
Amihud Illiquidity
Style
+1.49
1.7%
+0.46%
0.5%
Liquidity
Style
+0.34
1.1%
+0.32%
0.3%
Max Drawdown
Style
+0.68
1.1%
+0.29%
0.3%
Kurtosis
Style
+0.72
1.0%
+0.28%
0.3%
Short-term Reversal
Style
+0.19
0.6%
+0.16%
0.2%
Historical Volatility
Style
+0.21
0.5%
+0.14%
0.1%
Residual Volatility
Style
-0.10
-0.3%
-0.07%
-0.1%
Skewness
Style
+0.86
-0.8%
-0.22%
-0.2%
Non-linear Size
Style
+1.43
-1.2%
-0.33%
-0.3%
Size
Style
+0.31
-1.3%
-0.36%
-0.4%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
+0.31
+2.10
-1.79
Non-linear Size
+1.43
+1.68
-0.24
Mid Cap
+1.17
+0.13
+1.05
Beta
+0.33
+1.29
-0.97
Momentum
+1.05
+0.72
+0.33
Short-term Reversal
+0.19
-0.64
+0.83
Residual Volatility
-0.10
-0.40
+0.30
Historical Volatility
+0.21
+0.86
-0.65
Liquidity
+0.34
+0.11
+0.23
Amihud Illiquidity
+1.49
+1.16
+0.33
Turnover
-0.03
+0.21
-0.23
Growth
-0.04
+0.58
-0.62
Leverage (Downside Vol)
-0.57
+0.14
-0.71
Skewness
+0.86
+0.24
+0.63
Kurtosis
+0.72
+0.21
+0.51
Max Drawdown
+0.68
-0.08
+0.76
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-19.18%
+4.32%
+14.12%
-14.12%
+14.12%
Other
39.6%
0.0%
+1.24%
+0.00%
+5.27%
+0.00%
+0.49%
+0.49%
Communication Services
0.0%
2.6%
+0.00%
-15.54%
+0.06%
+0.41%
-0.41%
+0.41%
Utilities
0.0%
0.8%
+0.00%
+11.58%
-0.20%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.58%
-0.24%
-0.13%
+0.13%
-0.13%
Health Care
60.4%
1.7%
-0.25%
+9.16%
+13.19%
-0.16%
-5.53%
-0.31%
Consumer Discretionary
0.0%
8.8%
+0.00%
+5.56%
-1.66%
-0.49%
+0.49%
-0.49%
Industrials
0.0%
11.1%
+0.00%
+7.16%
-2.27%
-0.80%
+0.80%
-0.80%
Total
+18.36%
+12.82%
-18.02%
+13.17%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
IWM
ISHARES TR
Other
39.57%
+1.24%
+0.49%
New
ROIV
ROIVANT SCIENCES LTD
Health Care
16.66%
+8.09%
+1.35%
Reduce
INSM
INSMED INC
Health Care
9.17%
+6.15%
+0.56%
Reduce
MRNA
MODERNA INC
Health Care
6.86%
+15.99%
+1.10%
Reduce
RVMD
REVOLUTION MEDICINES INC
Health Care
6.58%
-16.06%
-1.06%
Reduce
ODTX
ODYSSEY THERAPEUTICS INC
Health Care
3.99%
-13.86%
-0.55%
Add
SGMT
SAGIMET BIOSCIENCES INC
Health Care
3.55%
+3.44%
+0.12%
Add
PTGX
PROTAGONIST THERAPEUTICS INC
Health Care
3.45%
-7.05%
-0.24%
Hold
RLAY
RELAY THERAPEUTICS INC
Health Care
2.19%
+0.22%
+0.01%
Reduce
MDGL
MADRIGAL PHARMACEUTICALS INC
Health Care
2.15%
-15.19%
-0.33%
Reduce
BEAM
BEAM THERAPEUTICS INC
Health Care
1.57%
-6.63%
-0.10%
New
CRSP
CRISPR THERAPEUTICS AG
Health Care
1.38%
-23.64%
-0.33%
Add
NAMS
NEWAMSTERDAM PHARMA COMPANY
Health Care
0.95%
-17.19%
-0.16%
Hold
TSHA
TAYSHA GENE THERAPIES INC
Health Care
0.69%
-15.81%
-0.11%
Reduce
NTLA
INTELLIA THERAPEUTICS INC
Health Care
0.60%
-19.57%
-0.12%
New
AVBP
ARRIVENT BIOPHARMA INC
Health Care
0.43%
-57.03%
-0.25%
Reduce
GENB
GENERATE BIOMEDICINES INC
Health Care
0.21%
-19.64%
-0.04%
Reduce
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
ROIV
Health Care
16.66%
+8.09%
+1.35%
2
MRNA
Health Care
6.86%
+15.99%
+1.10%
3
INSM
Health Care
9.17%
+6.15%
+0.56%
4
IWM
Other
39.57%
+1.24%
+0.49%
5
SGMT
Health Care
3.55%
+3.44%
+0.12%
6
RLAY
Health Care
2.19%
+0.22%
+0.01%
7
GENB
Health Care
0.21%
-19.64%
-0.04%
8
BEAM
Health Care
1.57%
-6.63%
-0.10%
9
AVBP
Health Care
0.43%
-57.03%
-0.25%
10
CRSP
Health Care
1.38%
-23.64%
-0.33%
11
MDGL
Health Care
2.15%
-15.19%
-0.33%
12
ODTX
Health Care
3.99%
-13.86%
-0.55%
13
RVMD
Health Care
6.58%
-16.06%
-1.06%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned +1.05%, versus -13.72% for the QQQ synthetic benchmark — an excess of +14.76%.
Return attribution: the largest positive style/industry contributions came from Kurtosis +5.05%, Health Care +4.91%, Other +3.98%; the largest drags came from Skewness -3.64%, Momentum -3.50%, Historical Volatility -2.70%. Specific (stock-level) return contributed -2.07%.
Risk attribution: Barra model volatility is 27.58% annualised; factor risk explains 71% of variance and specific risk 29%. The largest factor risk sources are Other 24.9%, Health Care 20.1%, Momentum 9.4%.
Style tilt: size +0.31, momentum +1.05, volatility +0.21, liquidity +0.34; the weighted raw beta is 1.18. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+58.7 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +18.36%, selection +12.82% and interaction -18.02%.
Concentration: the top-10 positions are 94.2% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Affinity Asset Advisors, LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, Affinity Asset Advisors, LLC reported 112 equity positions worth $2.15B in aggregate; its largest disclosed positions were IWM ($277.89M), ROIV ($117.02M), SYRE ($113.88M).
How large is Affinity Asset Advisors, LLC's portfolio?
Affinity Asset Advisors, LLC reported $2.15B of long equity holdings across 112 positions as of 2026-Q3. Top-10 holdings account for 46.3% of reported value.
What is Affinity Asset Advisors, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/affinity-asset-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>